Reduction versus abrupt cessation in smokers who want to quit.
Información
- DOI:
- https://doi.org/10.1002/14651858.CD008033Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 octubre 2009see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Tabaquismo
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Author's contributions will be reported in the full review.
Sources of support
Internal sources
-
Paul Aveyard, UK.
Paul Aveyard receives a salary part‐funded by the University of Birmingham
-
John Hughes, USA.
John Hughes receives a salary part‐funded by the University of Vermont
External sources
-
Paul Aveyard, UK.
Paul Aveyard's salary is part‐funded by the National Institute for Health Research and the National Health Service of the UK.
-
Nicola Lindson, UK.
Nicola Lindson was funded by the UK Centre for Tobacco Control Studies, a UKCRC Public Health Research: Centre of Excellence. Funding from British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the Department of Health, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged.
-
John Hughes, USA.
John Hughes' salary is part‐funded by Fletcher Allen Health Care
Declarations of interest
Dr Aveyard has done consultancy work for Pfizer, McNeil, and Xenova/Celtic.
Dr Hughes is currently employed by The University of Vermont and Fletcher Allen Health Care. In the last three years, he received research grants from the National Institutes of Health and Pfizer Pharmaceuticals and accepted honoraria or consulting fees from Abbot Pharmaceuticals; Academy for Educational Development; Acrux DDS; Aradigm; American Academy of Addiction Psychiatry, Atrium, Cambridge Consulting, Celtic Pharmaceuticals: Cline, Davis and Mann; Constella Condition; Concepts in Medicine; Consultants in Behavior Change; Cowen Inc; Cygnus; Edelman PR; EPI‐Q, Evotec; Exchange Limited; Fagerstrom Consulting; Free and Clear; Health Learning Systems; Healthwise; Insyght; Invivodata; Johns Hopkins University; J Reckner; Maine Medical Center; McNeil Pharmaceuticals; Nabi Pharmaceuticals; Novartis Pharmaceuticals; Oglivy Health PR, Pfizer Pharmaceuticals; Pinney Associates; Reuters; Shire Health London; Temple University of Health Sciences; United Biosource; The Universities of Arkansas, Auckland, Cantabria, Greifswald and Kentucky; US National Institutes of Health; Xenova and ZS Associates.
Version history
| Published | Title | Stage | Authors | Version |
| 2019 Oct 01 | Reduction versus abrupt cessation in smokers who want to quit | Review | Nicola Lindson, Paul Aveyard, John R Hughes | |
| 2012 Nov 14 | Reduction versus abrupt cessation in smokers who want to quit | Review | Nicola Lindson‐Hawley, Paul Aveyard, John R Hughes | |
| 2010 Mar 17 | Reduction versus abrupt cessation in smokers who want to quit | Review | Nicola Lindson, Paul Aveyard, John R Hughes | |
| 2009 Oct 07 | Reduction versus abrupt cessation in smokers who want to quit. | Protocol | Nicola Lindson, Paul Aveyard, John R Hughes | |
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Adult; Humans;
